Characterisation of Gene Variants in the Angiogenic Pathway
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00716287|
Recruitment Status : Unknown
Verified January 2014 by National University Hospital, Singapore.
Recruitment status was: Active, not recruiting
First Posted : July 16, 2008
Last Update Posted : January 14, 2014
Anti-angiogenic targeted therapies are used in a wide range of solid tumors including NSCLC, breast cancer, GISTs, CRC, renal cell carcinoma and hepatocellular carcinoma. Somatic mutations in genes related to tumorigenesis have been associated with treatment response whereas germline gene variants have been associated with tumor risk, prognosis and treatment related toxicity.Study objectives are:
- To characterise the prevalence and clinicopathological associations of germline and somatic variation in genes involved in the angiogenic pathway in healthy donors and unselected cancer patients
- To examine the association between angiogenic gene variants and outcome in patients receiving anti-angiogenic therapy
|Condition or disease|
|Study Type :||Observational|
|Official Title:||Characterisation of Gene Variants in the Angiogenic Pathway|
|Study Start Date :||March 2007|
|Estimated Primary Completion Date :||December 2014|
Anti-angiogenic targeted therapies are used in a wide range of solid tumors including NSCLC, breast cancer, GISTs, CRC, renal cell carcinoma and hepatocellular carcinoma.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00716287
|National University Hospital|
|Principal Investigator:||Ross Andrew Soo, MBBS||National University Hospital, Singapore|